Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Miles C Andrews"'
Autor:
Jack M Edwards, Miles C Andrews, Hayley Burridge, Robin Smith, Carole Owens, Mark Edinger, Katherine Pilkington, Juliette Desfrancois, Mark Shackleton, Sashendra Senthi, Menno C vanZelm
Publikováno v:
Clinical & Translational Immunology, Vol 12, Iss 9, Pp n/a-n/a (2023)
Abstract Objectives Despite the success of immune checkpoint blockade, most metastatic melanoma patients fail to respond to therapy or experience severe toxicity. Assessment of biomarkers and immunophenotypes before or early into treatment will help
Externí odkaz:
https://doaj.org/article/1fff49ff623d4f39912aa49f46f49291
Autor:
Shahneen Sandhu, David E Gyorki, Richard A Scolyer, George Au-Yeung, Grant A McArthur, Minyu Wang, Georgina Long, Angela Pizzolla, Paul Joseph Neeson, Soroor Zadeh, Kevin Thia, James S Wilmott, Miles C Andrews, Ali Weppler, Joseph A Trapani, Melissa J Davis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/a361f758191942e486d27c60762fc49d
Autor:
Michael P Smith, Emily J Rowling, Zsofia Miskolczi, Jennifer Ferguson, Loredana Spoerri, Nikolas K Haass, Olivia Sloss, Sophie McEntegart, Imanol Arozarena, Alex von Kriegsheim, Javier Rodriguez, Holly Brunton, Jivko Kmarashev, Mitchell P Levesque, Reinhard Dummer, Dennie T Frederick, Miles C Andrews, Zachary A Cooper, Keith T Flaherty, Jennifer A Wargo, Claudia Wellbrock
Publikováno v:
EMBO Molecular Medicine, Vol 9, Iss 8, Pp 1011-1029 (2017)
Abstract Approaches to prolong responses to BRAF targeting drugs in melanoma patients are challenged by phenotype heterogeneity. Melanomas of a “MITF‐high” phenotype usually respond well to BRAF inhibitor therapy, but these melanomas also conta
Externí odkaz:
https://doaj.org/article/7cabb6c3861544079d79157438ec0d09
Autor:
Akash Mitra, Miles C. Andrews, Whijae Roh, Marianna Petaccia De Macedo, Courtney W. Hudgens, Fernando Carapeto, Shailbala Singh, Alexandre Reuben, Feng Wang, Xizeng Mao, Xingzhi Song, Khalida Wani, Samantha Tippen, Kwok-Shing Ng, Aislyn Schalck, Donald A. Sakellariou-Thompson, Eveline Chen, Sangeetha M. Reddy, Christine N. Spencer, Diana Wiesnoski, Latasha D. Little, Curtis Gumbs, Zachary A. Cooper, Elizabeth M. Burton, Patrick Hwu, Michael A. Davies, Jianhua Zhang, Chantale Bernatchez, Nicholas Navin, Padmanee Sharma, James P. Allison, Jennifer A. Wargo, Cassian Yee, Michael T. Tetzlaff, Wen-Jen Hwu, Alexander J. Lazar, P. Andrew Futreal
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-18 (2020)
Immunotherapies now dominate the treatment landscape for melanoma, but why they only work in a subset of patients remains unclear. Here, the authors perform an immunogenomic analysis on 67 intratumor sub-regions of a PD-1 inhibitor resistant melanoma
Externí odkaz:
https://doaj.org/article/97e9b4c4c8f048e9a752f694b5bd17ef
Autor:
Elena Galvani, Piyushkumar A. Mundra, Sara Valpione, Pablo Garcia-Martinez, Matthew Smith, Jonathan Greenall, Rohit Thakur, Beth Helmink, Miles C. Andrews, Louis Boon, Christopher Chester, Gabriela Gremel, Kate Hogan, Amit Mandal, Kang Zeng, Antonia Banyard, Garry Ashton, Martin Cook, Paul Lorigan, Jennifer A. Wargo, Nathalie Dhomen, Richard Marais
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
Identification of clinical relevant biomarkers to predict response to immune checkpoint blockade (ICB) in melanoma remains challenging. Here, the authors show that stroma remodelling and reduced cell division are associated with durable response to a
Externí odkaz:
https://doaj.org/article/a043c3f4d304486f94686720bc3b8706
Autor:
Gamze Kuser-Abali, Youfang Zhang, Pacman Szeto, Peinan Zhao, Samar Masoumi-Moghaddam, Clare G. Fedele, Isobel Leece, Cheng Huang, Jen G. Cheung, Malaka Ameratunga, Fumihito Noguchi, Miles C. Andrews, Nicholas C. Wong, Ralf B. Schittenhelm, Mark Shackleton
Publikováno v:
Oncogene. 42:1360-1373
Cellular heterogeneity in cancer is linked to disease progression and therapy response, although mechanisms regulating distinct cellular states within tumors are not well understood. We identified melanin pigment content as a major source of cellular
Autor:
Michael G. White, Robert Szczepaniak Sloane, Russell G. Witt, Alexandre Reuben, Pierre Olivier Gaudreau, Miles C. Andrews, Ningping Feng, Sarah Johnson, Caleb A. Class, Christopher Bristow, Khalida Wani, Courtney Hudgens, Luigi Nezi, Teresa Manzo, Mariana Pettaccia De Macedo, Jianhua Hu, Richard Davis, Hong Jiang, Peter Prieto, Elizabeth Burton, Patrick Hwu, Hussein Tawbi, Jeffrey Gershenwald, Alexander J. Lazar, Michael T. Tetzlaff, Willem Overwijk, Scott E Woodman, Zachary A. Cooper, Joseph R. Marszalek, Michael A. Davies, Timothy P. Heffernan, Jennifer A. Wargo
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Targeted and immunotherapy regimens have revolutionized the treatment of advanced melanoma patients. Despite this, only a subset of patients respond durably. Recently, combination strategies of BRAF/MEK inhibitors with immune checkpoint inhibitor mon
Externí odkaz:
https://doaj.org/article/e6152b9f5495402183474ea2dacf7022
Publikováno v:
Trends in Cancer. 9:3-5
Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, many patients fail to respond to this therapy or experience side effects. Recently, gut microbiota have emerged as a key determinant of ICB efficacy and toxicity, making m
Autor:
Candani S. A. Tutuka, Miles C. Andrews, John M. Mariadason, Paul Ioannidis, Christopher Hudson, Jonathan Cebon, Andreas Behren
Publikováno v:
Molecular Cancer, Vol 16, Iss 1, Pp 1-5 (2017)
Abstract BRAF inhibitors (BRAFi) are standard of care for the treatment of BRAF V600 mutation-driven metastatic melanoma, but can lead to paradoxical activation of the mitogen-activated protein kinase (MAPK) signalling pathway. This can result in the
Externí odkaz:
https://doaj.org/article/52659a72efb14eaba7327e7008ad3690
Autor:
Jonathan Cebon, Andreas Behren, Andrew P. Grigg, Andrew W. Roberts, Janis Boyd, Natalie Turner, Miles C. Andrews
Purpose: Targeted MEK inhibition is an emerging therapy in a number of solid tumors. It holds particular promise in BRAF V600E mutation–positive malignant melanoma, where constitutive activation and cell growth through the MAP kinase (MAPK) pathway
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1be731fee81f7cc87e76d5cb994ec4c4
https://doi.org/10.1158/1078-0432.c.6524607.v1
https://doi.org/10.1158/1078-0432.c.6524607.v1